Yulong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yulong Xu has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Changning Wang
Harvard Medical School
17 shared publications Yongle Wang
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
12 shared publicationsYanli Wang
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
9 shared publications- Yanli Wang
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital
8 shared publications - Hua Cheng
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital
7 shared publications - Can Zhang
Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, United States
6 shared publications
Latest Publications
- 8 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109970
The design, synthesis and evaluation of the first carbon-11 positron emission tomography radiotracer for ASK1 imaging
- 8 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109970
The design, synthesis and evaluation of the first carbon-11 positron emission tomography radiotracer for ASK1 imaging
- 25 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (9) , 1779-1786
Synthesis and Evaluation of a PET Radiotracer [ 18 F]LY3000328 Selectively Targeting the Cysteine Protease Cathepsin S
Cathepsin S (Cat S) is a cysteine protease broadly expressed in the brain and a key mediator of neuroinflammatory processes, making it an attractive target for molecular imaging agents and drug development. Here, we report the development and evaluation of [18F]LY3000328, a positron emission tomography (PET) radiotracer that selectively targets Cat S and is derived directly from the clinical Cat S inhibitor LY3000328. [18F]LY3000328 was synthesized via a ruthenium-assisted late-stage 18F-deoxyfluorination of the corresponding phenol precursor. In vitro autoradiography, the marked reduction in tracer uptake under blocking conditions suggests specific binding of [18F]LY3000328 to Cat S, and the significantly higher uptake in transgenic 5xFAD mouse brain sections indicates upregulation of Cat S in Alzheimer's disease (AD), consistent with previously reported findings. However, in vivo PET imaging in wild-type mice revealed low blood-brain barrier (BBB) penetration and no significant reduction under blocking conditions, suggesting that limited BBB permeability may constrain its efficiency as a brain PET tracer. Despite its limited brain penetration, these results suggest that [18F]LY3000328 may serve as a useful starting scaffold for further optimization of physicochemical and pharmacokinetic properties toward Cat S-targeted PET imaging of neuroinflammation in AD and potentially other neurodegenerative disorders.
- 25 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (9) , 1779-1786
Synthesis and Evaluation of a PET Radiotracer [ 18 F]LY3000328 Selectively Targeting the Cysteine Protease Cathepsin S
Cathepsin S (Cat S) is a cysteine protease broadly expressed in the brain and a key mediator of neuroinflammatory processes, making it an attractive target for molecular imaging agents and drug development. Here, we report the development and evaluation of [18F]LY3000328, a positron emission tomography (PET) radiotracer that selectively targets Cat S and is derived directly from the clinical Cat S inhibitor LY3000328. [18F]LY3000328 was synthesized via a ruthenium-assisted late-stage 18F-deoxyfluorination of the corresponding phenol precursor. In vitro autoradiography, the marked reduction in tracer uptake under blocking conditions suggests specific binding of [18F]LY3000328 to Cat S, and the significantly higher uptake in transgenic 5xFAD mouse brain sections indicates upregulation of Cat S in Alzheimer's disease (AD), consistent with previously reported findings. However, in vivo PET imaging in wild-type mice revealed low blood-brain barrier (BBB) penetration and no significant reduction under blocking conditions, suggesting that limited BBB permeability may constrain its efficiency as a brain PET tracer. Despite its limited brain penetration, these results suggest that [18F]LY3000328 may serve as a useful starting scaffold for further optimization of physicochemical and pharmacokinetic properties toward Cat S-targeted PET imaging of neuroinflammation in AD and potentially other neurodegenerative disorders.
- 24 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (9) , 1802-1808
The Development of the Novel Positron Emission Tomography Radiotracer for Selective HDAC8 Imaging
HDACs play important roles in various neurological disorders. Unlike other HDAC subtypes that have been extensively studied in neurodegenerative diseases, HDAC8 has only recently emerged as a regulator in the central nervous system. In this study, we designed and successfully radiosynthesized [11C]HYF031 as a potential HDAC8 radioligand with acceptable radiochemical yield and purity. In vitro autoradiography and self-blocking dynamic PET/CT studies in C57BL/6 mice demonstrated specific binding of [11C]HYF031 to HDAC proteins in the brain. Dynamic PET imaging further showed measurable brain uptake and pharmacokinetic properties compatible with PET imaging. Biodistribution studies indicated that the tracer is primarily metabolized through the hepatobiliary system. Overall, these results suggest that [11C]HYF031 is a promising lead tracer for HDAC8 imaging.
- 24 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (9) , 1802-1808
The Development of the Novel Positron Emission Tomography Radiotracer for Selective HDAC8 Imaging
HDACs play important roles in various neurological disorders. Unlike other HDAC subtypes that have been extensively studied in neurodegenerative diseases, HDAC8 has only recently emerged as a regulator in the central nervous system. In this study, we designed and successfully radiosynthesized [11C]HYF031 as a potential HDAC8 radioligand with acceptable radiochemical yield and purity. In vitro autoradiography and self-blocking dynamic PET/CT studies in C57BL/6 mice demonstrated specific binding of [11C]HYF031 to HDAC proteins in the brain. Dynamic PET imaging further showed measurable brain uptake and pharmacokinetic properties compatible with PET imaging. Biodistribution studies indicated that the tracer is primarily metabolized through the hepatobiliary system. Overall, these results suggest that [11C]HYF031 is a promising lead tracer for HDAC8 imaging.
- 3 March 2026
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 156-157, 109620
Development of a new 18F-labeled PET tracer for potential application to HDAC2 neuroimaging
- 3 March 2026
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 156-157, 109620
Development of a new 18F-labeled PET tracer for potential application to HDAC2 neuroimaging
- 22 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (1) , 231-238
Development of a Novel PET Radioligand for Imaging the Adenosine A 2A Receptor in the Brain
The adenosine A2A receptor (A2AAR) is implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, due to its involvement in neuroinflammatory processes and synaptic function. However, suitable positron emission tomography (PET) radioligands for direct imaging of A2AAR in the living brain remain limited. In this study, we describe the synthesis and preclinical evaluation of [11C]2, a novel PET radioligand developed to target A2AAR with moderate affinity and selectivity. [11C]2 was synthesized with high radiochemical purity and satisfactory molar activity. In vivo PET imaging in wild-type mice demonstrated that [11C]2 efficiently crossed the blood-brain barrier and distributed throughout the brain. Blocking studies with unlabeled compound 2 confirmed the specificity of [11C]2 binding in vivo. In vitro autoradiography further revealed regional binding patterns in both wild-type and Alzheimer's disease model mice. Slightly higher in vitro signals in AD model mice suggest a potential link to neuroinflammatory mechanisms, although further investigation is required. Notably, during the initial 0.5-2.5 min after injection, striatal uptake was modestly higher than in other brain regions; however, this advantage became indistinct at later time points. Thus, while [11C]2 enables very early phase mapping of A2AAR distribution, the transient nature of its striatal preference indicates that further structural optimization is required to enhance sustained striatal selectivity and overall imaging performance.
- 22 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (1) , 231-238
Development of a Novel PET Radioligand for Imaging the Adenosine A 2A Receptor in the Brain
The adenosine A2A receptor (A2AAR) is implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, due to its involvement in neuroinflammatory processes and synaptic function. However, suitable positron emission tomography (PET) radioligands for direct imaging of A2AAR in the living brain remain limited. In this study, we describe the synthesis and preclinical evaluation of [11C]2, a novel PET radioligand developed to target A2AAR with moderate affinity and selectivity. [11C]2 was synthesized with high radiochemical purity and satisfactory molar activity. In vivo PET imaging in wild-type mice demonstrated that [11C]2 efficiently crossed the blood-brain barrier and distributed throughout the brain. Blocking studies with unlabeled compound 2 confirmed the specificity of [11C]2 binding in vivo. In vitro autoradiography further revealed regional binding patterns in both wild-type and Alzheimer's disease model mice. Slightly higher in vitro signals in AD model mice suggest a potential link to neuroinflammatory mechanisms, although further investigation is required. Notably, during the initial 0.5-2.5 min after injection, striatal uptake was modestly higher than in other brain regions; however, this advantage became indistinct at later time points. Thus, while [11C]2 enables very early phase mapping of A2AAR distribution, the transient nature of its striatal preference indicates that further structural optimization is required to enhance sustained striatal selectivity and overall imaging performance.
- 20 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 25456-25468
Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization
Targeting pyruvate kinase M2 (PKM2) offers a route to probe neuroinflammatory metabolism in Alzheimer’s disease (AD). We report the radiosynthesis and preclinical evaluation of a PKM2-targeted PET radioligand, [11C]7d. [11C]7d was produced in 21.6–29.4% decay-corrected yield from trapped [11C]CH3I with >95% radiochemical purity. Whole-body PET (0–60 min) indicated predominantly hepatobiliary clearance with modest renal excretion. In wild-type mice, [11C]7d showed rapid brain entry followed by washout consistent with reversible kinetics. Pharmacological pretreatment with 7d reduced whole-brain AUC, indicating displaceable binding. Ex vivo autoradiography showed a 62.8% signal reduction with 7d and ∼20.1% higher binding in 5xFAD versus NonTg sections. In vivo, 5xFAD mice displayed higher uptake; cerebellum normalized SUVR(20–60 min) increased across multiple regions. PKM2 immunohistochemistry supported regional target engagement. These data support [11C]7d as a tool for noninvasive visualization of PKM2-linked glycolytic alterations in the living brain and motivate further quantitative and translational studies.
- 20 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 25456-25468
Development of a Novel PET Radioligand Targeting PKM2 for Brain Imaging and Alzheimer’s Disease Characterization
Targeting pyruvate kinase M2 (PKM2) offers a route to probe neuroinflammatory metabolism in Alzheimer’s disease (AD). We report the radiosynthesis and preclinical evaluation of a PKM2-targeted PET radioligand, [11C]7d. [11C]7d was produced in 21.6–29.4% decay-corrected yield from trapped [11C]CH3I with >95% radiochemical purity. Whole-body PET (0–60 min) indicated predominantly hepatobiliary clearance with modest renal excretion. In wild-type mice, [11C]7d showed rapid brain entry followed by washout consistent with reversible kinetics. Pharmacological pretreatment with 7d reduced whole-brain AUC, indicating displaceable binding. Ex vivo autoradiography showed a 62.8% signal reduction with 7d and ∼20.1% higher binding in 5xFAD versus NonTg sections. In vivo, 5xFAD mice displayed higher uptake; cerebellum normalized SUVR(20–60 min) increased across multiple regions. PKM2 immunohistochemistry supported regional target engagement. These data support [11C]7d as a tool for noninvasive visualization of PKM2-linked glycolytic alterations in the living brain and motivate further quantitative and translational studies.
- 8 May 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 192 (Pt B) , 110324
Synthesis and characterization of a new Carbon-11 labeled positron emission tomography radiotracer for RIPK1 neuroimaging
- 8 May 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 192 (Pt B) , 110324
Synthesis and characterization of a new Carbon-11 labeled positron emission tomography radiotracer for RIPK1 neuroimaging
- 21 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7605-7614
Design and Development of a Novel BET Protein-Targeted PET Imaging Probe for In Vivo Characterization of Alzheimer’s Disease Pathophysiology
BET proteins are essential epigenetic regulators involved in gene transcription and have been linked to neurodegenerative disorders, such as Alzheimer's disease (AD). In vivo imaging of BET proteins may provide insights into disease pathophysiology and help identify potential therapeutic targets. We developed a carbon-11-labeled radiotracer, [11C]YL9, which exhibits high binding affinity for BET proteins. It was synthesized via standard methylation and evaluated for brain uptake, binding specificity, and pharmacokinetics in wild-type and AD mouse models using PET imaging and autoradiography. [11C]YL9 demonstrated excellent blood-brain barrier penetration, prolonged retention, and strong BET protein binding. In AD mice, [11C]YL9 uptake was significantly higher than in wild-type mice, suggesting increased BET protein availability. These findings suggest that [11C]YL9 is a promising PET radioligand for noninvasive BET protein imaging. Its high specificity and favorable pharmacokinetics make it a valuable tool for studying BET protein involvement in neurodegeneration.
- 21 March 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7605-7614
Design and Development of a Novel BET Protein-Targeted PET Imaging Probe for In Vivo Characterization of Alzheimer’s Disease Pathophysiology
BET proteins are essential epigenetic regulators involved in gene transcription and have been linked to neurodegenerative disorders, such as Alzheimer's disease (AD). In vivo imaging of BET proteins may provide insights into disease pathophysiology and help identify potential therapeutic targets. We developed a carbon-11-labeled radiotracer, [11C]YL9, which exhibits high binding affinity for BET proteins. It was synthesized via standard methylation and evaluated for brain uptake, binding specificity, and pharmacokinetics in wild-type and AD mouse models using PET imaging and autoradiography. [11C]YL9 demonstrated excellent blood-brain barrier penetration, prolonged retention, and strong BET protein binding. In AD mice, [11C]YL9 uptake was significantly higher than in wild-type mice, suggesting increased BET protein availability. These findings suggest that [11C]YL9 is a promising PET radioligand for noninvasive BET protein imaging. Its high specificity and favorable pharmacokinetics make it a valuable tool for studying BET protein involvement in neurodegeneration.
- Open Access
- 11 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (12) , 1670
Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization
Background: Bromodomain and extra-terminal (BET) proteins are critical regulators of gene transcription, as they recognize acetylated lysine residues. The BD1 bromodomain of BRD4, a member of the BET family, has emerged as a promising therapeutic target for various diseases. This study aimed to develop and evaluate a novel C-11 labeled PET radiotracer, [11C]YL10, for imaging the BD1 bromodomain of BRD4 in vivo. Methods: [11C]YL10 was synthesized and evaluated for its ability to bind to the BD1 bromodomain selectively. PET imaging studies were conducted in mice to assess brain penetration, pharmacokinetics, and selectivity. In vitro autoradiography and blocking experiments were performed to confirm the tracer’s specificity for the BD1 domain. Results: [11C]YL10 demonstrated good brain penetration, high selectivity for the BD1 bromodomain, and favorable pharmacokinetics in initial PET imaging studies. In vitro autoradiography and blocking experiments confirmed the specific binding of [11C]YL10 to the BD1 domain of BRD4, further validating its potential as a targeted radiotracer. Conclusions: The development of [11C]YL10 provides a new tool for studying BRD4 bromodomains using PET imaging technology. This radiotracer offers potential advancement in the diagnosis and research of neurodegenerative diseases and related disorders involving BRD4 dysregulation.
- 11 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (12) , 1670
Open AccessDevelopment of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization
Background: Bromodomain and extra-terminal (BET) proteins are critical regulators of gene transcription, as they recognize acetylated lysine residues. The BD1 bromodomain of BRD4, a member of the BET family, has emerged as a promising therapeutic target for various diseases. This study aimed to develop and evaluate a novel C-11 labeled PET radiotracer, [11C]YL10, for imaging the BD1 bromodomain of BRD4 in vivo. Methods: [11C]YL10 was synthesized and evaluated for its ability to bind to the BD1 bromodomain selectively. PET imaging studies were conducted in mice to assess brain penetration, pharmacokinetics, and selectivity. In vitro autoradiography and blocking experiments were performed to confirm the tracer’s specificity for the BD1 domain. Results: [11C]YL10 demonstrated good brain penetration, high selectivity for the BD1 bromodomain, and favorable pharmacokinetics in initial PET imaging studies. In vitro autoradiography and blocking experiments confirmed the specific binding of [11C]YL10 to the BD1 domain of BRD4, further validating its potential as a targeted radiotracer. Conclusions: The development of [11C]YL10 provides a new tool for studying BRD4 bromodomains using PET imaging technology. This radiotracer offers potential advancement in the diagnosis and research of neurodegenerative diseases and related disorders involving BRD4 dysregulation.